Suppr超能文献

奥地利的 SARS-CoV-2 再感染风险。

SARS-CoV-2 re-infection risk in Austria.

机构信息

Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.

出版信息

Eur J Clin Invest. 2021 Apr;51(4):e13520. doi: 10.1111/eci.13520. Epub 2021 Feb 21.

Abstract

BACKGROUND

A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria.

METHODS

This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive.

RESULTS

We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13).

CONCLUSIONS

We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.

摘要

背景

关于 2019 年冠状病毒病(COVID-19)的一个关键问题是,以前感染过严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的个体对这种疾病的免疫力有多有效和持久。我们旨在评估奥地利普通人群中 SARS-CoV-2 再次感染的风险。

方法

这是一项使用奥地利流行病学报告系统的国家 SARS-CoV-2 感染数据的回顾性观察性研究。作为主要结果,我们旨在通过跟踪两组在 2020 年 9 月 1 日至 11 月 30 日的第二波中聚合酶链反应(PCR)确认的感染,比较第一波(2020 年 2 月至 4 月 30 日)COVID-19 幸存者与其余普通人群中首次感染的 SARS-CoV-2 再感染的几率。再感染计数是暂定的,因为不能排除第一波和/或第二波中的阳性 PCR 可能是假阳性。

结果

我们记录了第一波 COVID-19 幸存者中的 40 例暂定再感染(0.27%)和剩余普通人群中的 253 581 例感染(2.85%),这转化为比值比(95%置信区间)为 0.09(0.07 至 0.13)。

结论

我们观察到 SARS-CoV-2 在奥地利的再感染率相对较低。自然感染后对 SARS-CoV-2 的保护作用与疫苗效力的最高现有估计值相当。需要进一步对此问题进行精心设计的研究,以改善基于证据的公共卫生措施和疫苗接种策略决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c746/7994970/effe7e4cea1e/ECI-51-e13520-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验